These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 31563255)

  • 1. A Cost Analysis and Cost-Utility Analysis of a Community Pharmacist-Led Intervention on Reducing Cardiovascular Risk: The Alberta Vascular Risk Reduction Community Pharmacy Project (R
    Tam-Tham H; Clement F; Hemmelgarn BR; Manns BJ; Klarenbach SW; Tonelli M; Tsuyuki RT; Al Hamarneh YN; Penko J; Weaver CGW; Au F; Weaver RG; Jones CA; McBrien KA
    Value Health; 2019 Oct; 22(10):1128-1136. PubMed ID: 31563255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled RxEACH Trial.
    Tsuyuki RT; Al Hamarneh YN; Jones CA; Hemmelgarn BR
    J Am Coll Cardiol; 2016 Jun; 67(24):2846-54. PubMed ID: 27058907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Patients With CKD: A Subgroup Analysis of the Randomized Controlled R
    Al Hamarneh YN; Tsuyuki RT; Jones CA; Manns B; Tonelli M; Scott-Douglass N; Jindal K; Tink W; Hemmelgarn BR
    Am J Kidney Dis; 2018 Jan; 71(1):42-51. PubMed ID: 28912054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension in the United States.
    Dixon DL; Johnston K; Patterson J; Marra CA; Tsuyuki RT
    JAMA Netw Open; 2023 Nov; 6(11):e2341408. PubMed ID: 37921763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Adult Patients with Type 2 Diabetes: The Multicentre Randomized Controlled R
    Al Hamarneh YN; Hemmelgarn BR; Hassan I; Jones CA; Tsuyuki RT
    Can J Diabetes; 2017 Dec; 41(6):580-586. PubMed ID: 28965748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).
    Houle SK; Chuck AW; McAlister FA; Tsuyuki RT
    Pharmacotherapy; 2012 Jun; 32(6):527-37. PubMed ID: 22552863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact of community pharmacist intervention in cholesterol risk management: an evaluation of the study of cardiovascular risk intervention by pharmacists.
    Simpson SH; Johnson JA; Tsuyuki RT
    Pharmacotherapy; 2001 May; 21(5):627-35. PubMed ID: 11349751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacist prescribing and care improves cardiovascular risk, but is it cost-effective? A cost-effectiveness analysis of the R
    Al Hamarneh YN; Johnston K; Marra CA; Tsuyuki RT
    Can Pharm J (Ott); 2019; 152(4):257-266. PubMed ID: 31320960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial.
    Majumdar SR; Johnson JA; Lier DA; Russell AS; Hanley DA; Blitz S; Steiner IP; Maksymowych WP; Morrish DW; Holroyd BR; Rowe BH
    Osteoporos Int; 2007 Mar; 18(3):261-70. PubMed ID: 17086470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of a community pharmacist-led medicines management service for patients with coronary heart disease in England: healthcare system and patient perspectives.
    Scott A; Tinelli M; Bond C;
    Pharmacoeconomics; 2007; 25(5):397-411. PubMed ID: 17488138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of adding pharmacists to primary care teams to reduce cardiovascular risk in patients with Type 2 diabetes: results from a randomized controlled trial.
    Simpson SH; Lier DA; Majumdar SR; Tsuyuki RT; Lewanczuk RZ; Spooner R; Johnson JA
    Diabet Med; 2015 Jul; 32(7):899-906. PubMed ID: 25594919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of pharmacist-led care versus usual care in type 2 diabetic Jordanians: a Markov modeling of cardiovascular diseases prevention.
    Mousa R; Hammad E
    Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1069-1079. PubMed ID: 33213221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. R
    Al Hamarneh YN; Marra C; Gniadecki R; Keeling S; Morgan A; Tsuyuki R
    BMJ Open; 2021 Mar; 11(3):e043612. PubMed ID: 33762234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of a statewide public health intervention to reduce cardiovascular disease risk.
    Smith L; Atherly A; Campbell J; Flattery N; Coronel S; Krantz M
    BMC Public Health; 2019 Sep; 19(1):1234. PubMed ID: 31492118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia.
    Bunting BA; Smith BH; Sutherland SE
    J Am Pharm Assoc (2003); 2008; 48(1):23-31. PubMed ID: 18192127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP): a randomized trial design of the effect of a community pharmacist intervention program on serum cholesterol risk.
    Tsuyuki RT; Johnson JA; Teo KK; Ackman ML; Biggs RS; Cave A; Chang WC; Dzavik V; Farris KB; Galvin D; Semchuk W; Simpson SH; Taylor JG
    Ann Pharmacother; 1999 Sep; 33(9):910-9. PubMed ID: 10492489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Financial analysis of cardiovascular wellness program provided to self-insured company from pharmaceutical care provider's perspective.
    Wilson JB; Osterhaus MC; Farris KB; Doucette WR; Currie JD; Bullock T; Kumbera P
    J Am Pharm Assoc (2003); 2005; 45(5):588-92. PubMed ID: 16295644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic appraisal of a community-wide cardiovascular health awareness program.
    Goeree R; von Keyserlingk C; Burke N; He J; Kaczorowski J; Chambers L; Dolovich L; Michael Paterson J; Zagorski B
    Value Health; 2013; 16(1):39-45. PubMed ID: 23337214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial.
    Murray MD; Young J; Hoke S; Tu W; Weiner M; Morrow D; Stroupe KT; Wu J; Clark D; Smith F; Gradus-Pizlo I; Weinberger M; Brater DC
    Ann Intern Med; 2007 May; 146(10):714-25. PubMed ID: 17502632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.